H.C. Wainwright analyst Robert Burns raised the firm’s price target on Exelixis (EXEL) to $53 from $47 and keeps a Buy rating on the shares after Exelixis last week announced top-line results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab demonstrated a statistically significant improvement in overall survival vs. Stivarga in the intent-to-treat population. This success in the ITT population of the Phase 3 pivotal trial paves the path towards regulatory approval, the analyst tells investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.